Using imaging and blood tests to predict chemo response in gastric cancer
Part of Cancer, Digestive system clinical trials.
This trial uses a combination of CT scans, ultrasound, and blood tests to predict how well chemotherapy will work for people with locally advanced gastric cancer. The goal is to personalize treatment by identifying who will respond best to neoadjuvant chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a confirmed diagnosis of locally advanced gastric cancer that can be treated with chemotherapy before surgery.
- You need to have had a special ultrasound and CT scan of your stomach before starting chemotherapy.
- You must be able to provide a blood sample before chemotherapy for genetic and protein testing.
- You must agree to have the tumor tissue examined after surgery to see how well the chemotherapy worked.
- You should be willing to follow all study procedures and provide follow-up information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at stomach (or stomach–esophagus junction) cancer tissue, treatment details, and patient-reported experiences to better predict how you may respond to standard chemotherapy. It may help personalize future treatment by identifying markers that connect your tumor environment and your expected outcomes.
This study looks for ways to predict whether neoadjuvant chemotherapy (chemo given before surgery) will work well in people with locally advanced stomach cancer. It may help doctors choose the best treatment plan sooner based on your test results.
This research study analyzes tumor tissue samples to understand why some patients respond better to chemotherapy after gastric cancer surgery. By studying how genes are processed in cancer cells, researchers hope to predict which patients will benefit most from treatment.
This trial is testing a personalized treatment approach for advanced gastric cancer. It uses unique markers in your tumor (HER2, CLDN18.2, PD-L1) to match you with targeted therapies, aiming for better results than standard chemotherapy.
This trial tests a computer-based model that uses CT scans, endoscopic images, and biopsy tissue to predict how well stomach cancer will respond to chemotherapy given before surgery. The goal is to help doctors choose the best treatment for each patient.
This study uses special blood tests to detect cancer DNA and help doctors decide the best treatment plan for gastric cancer. The goal is to improve outcomes by personalizing therapy based on how your cancer responds.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.